Egetis Therapeutics AB (publ)

OM:EGTX Stock Report

Market Cap: SEK 1.9b

Egetis Therapeutics Valuation

Is EGTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EGTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EGTX (SEK5.34) is trading below our estimate of fair value (SEK137.79)

Significantly Below Fair Value: EGTX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EGTX?

Key metric: As EGTX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EGTX. This is calculated by dividing EGTX's market cap by their current revenue.
What is EGTX's PS Ratio?
PS Ratio28.3x
SalesSEK 67.90m
Market CapSEK 1.92b

Price to Sales Ratio vs Peers

How does EGTX's PS Ratio compare to its peers?

The above table shows the PS ratio for EGTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11x
DVYSR Devyser Diagnostics
10.8x31.4%SEK 2.1b
HNSA Hansa Biopharma
11x47.3%SEK 2.1b
CRNO B Cereno Scientific
16x-171.6%SEK 1.4b
PROB Probi
6.3x5.3%SEK 4.0b
EGTX Egetis Therapeutics
28.3x81.7%SEK 1.9b

Price-To-Sales vs Peers: EGTX is expensive based on its Price-To-Sales Ratio (28.3x) compared to the peer average (11x).

Price to Sales Ratio vs Industry

How does EGTX's PS Ratio compare vs other companies in the SE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.5x61.1%US$26.67m
SPRINT Sprint Bioscience
1.8x27.6%US$9.89m
PMDS PMD Device Solutions
0.9x62.0%US$3.19m
GEAN Genetic Analysis
1.1xn/aUS$1.96m
EGTX 28.3xIndustry Avg. 12.2xNo. of Companies6PS0816243240+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: EGTX is expensive based on its Price-To-Sales Ratio (28.3x) compared to the Swedish Biotechs industry average (12.2x).

Price to Sales Ratio vs Fair Ratio

What is EGTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EGTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio28.3x
Fair PS Ratio6.9x

Price-To-Sales vs Fair Ratio: EGTX is expensive based on its Price-To-Sales Ratio (28.3x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EGTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 5.34
SEK 10.80
+102.2%
25.8%SEK 14.00SEK 6.00n/a5
Nov ’25SEK 4.31
SEK 11.40
+164.5%
26.4%SEK 15.00SEK 6.00n/a5
Oct ’25SEK 4.59
SEK 11.40
+148.4%
26.4%SEK 15.00SEK 6.00n/a5
Sep ’25SEK 5.80
SEK 11.40
+96.6%
26.4%SEK 15.00SEK 6.00n/a5
Aug ’25SEK 5.87
SEK 13.30
+126.6%
32.7%SEK 18.00SEK 6.00n/a5
Jul ’25SEK 4.73
SEK 13.30
+181.2%
32.7%SEK 18.00SEK 6.00n/a5
Jun ’25SEK 8.08
SEK 14.30
+77.0%
20.2%SEK 18.00SEK 11.00n/a5
May ’25SEK 6.38
SEK 13.13
+105.7%
19.5%SEK 17.50SEK 11.00n/a4
Apr ’25SEK 6.68
SEK 13.13
+96.5%
19.5%SEK 17.50SEK 11.00n/a4
Mar ’25SEK 6.61
SEK 13.13
+98.6%
19.5%SEK 17.50SEK 11.00n/a4
Feb ’25SEK 5.78
SEK 12.75
+120.6%
15.1%SEK 16.00SEK 11.00n/a4
Jan ’25SEK 5.58
SEK 11.10
+98.9%
32.0%SEK 16.00SEK 5.00n/a5
Dec ’24SEK 4.76
SEK 11.10
+133.2%
32.0%SEK 16.00SEK 5.00n/a5
Nov ’24SEK 4.53
SEK 11.10
+145.0%
32.0%SEK 16.00SEK 5.00SEK 4.315
Oct ’24SEK 4.50
SEK 11.10
+146.7%
32.0%SEK 16.00SEK 5.00SEK 4.595
Sep ’24SEK 4.33
SEK 11.10
+156.4%
32.0%SEK 16.00SEK 5.00SEK 5.805
Aug ’24SEK 4.31
SEK 11.50
+166.8%
36.1%SEK 18.00SEK 5.00SEK 5.875
Jul ’24SEK 4.30
SEK 13.90
+223.3%
18.5%SEK 18.00SEK 10.50SEK 4.735
Jun ’24SEK 4.86
SEK 14.50
+198.4%
14.5%SEK 18.00SEK 11.50SEK 8.085
May ’24SEK 8.92
SEK 16.50
+85.0%
26.0%SEK 24.00SEK 11.50SEK 6.385
Apr ’24SEK 7.93
SEK 16.50
+108.1%
26.0%SEK 24.00SEK 11.50SEK 6.685
Mar ’24SEK 5.12
SEK 14.63
+185.6%
15.9%SEK 18.00SEK 11.50SEK 6.614
Feb ’24SEK 6.10
SEK 15.67
+156.8%
10.8%SEK 18.00SEK 14.00SEK 5.783
Jan ’24SEK 7.10
SEK 17.75
+150.0%
22.0%SEK 24.00SEK 14.00SEK 5.584
Dec ’23SEK 4.06
SEK 15.67
+285.9%
39.8%SEK 24.00SEK 9.00SEK 4.763
Nov ’23SEK 3.95
SEK 16.50
+318.3%
45.5%SEK 24.00SEK 9.00SEK 4.532

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

7D

5.0%

1Y

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

7D

-2.7%

1Y

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

7D

-8.1%

1Y

n/a